Biotech News
Related news
ACRSAclaris Therapeutics2026-09-03 12:00 EST
Aclaris Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
XFORX4 Pharmaceuticals2026-09-09 11:00 EST
X4 Pharmaceuticals to Participate in a Fireside Chat at the 2026 Wells Fargo Healthcare Conference
AVTXAvalo Therapeutics2026-07-22 11:00 EST
Avalo Therapeutics to Participate in the BTIG Biotechnology Conference
KNSAKiniksa2026-09-04 20:01 EST
Kiniksa Pharmaceuticals to Present at Wells Fargo 21st Annual Healthcare Conference
XGNExagen2026-07-28 13:00 EST
Exagen Inc. to Participate in Upcoming Investor Conference
GRIGRI Bio2026-08-27 14:01 EST
GRI Bio Featured in "Why Now" On-Demand Video Webcast
BMYBMYBristol-Myers Squibb Company2026-08-29 15:00 EST
Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European Society of Cardiology (ESC) Congress 2026
ZURAZura Bio2026-08-21 23:57 EST
Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
KNSAKiniksa2026-08-07 20:01 EST
Kiniksa Pharmaceuticals to Present at Canaccord Genuity 46th Annual Growth Conference
IMMPImmutep Limited2026-07-24 12:00 EST
Immutep Announces Abstract Accepted for Presentation at the European Society for Medical Oncology (ESMO) Congress 2026
Zura Bio
Autoimmune and Inflammatory Diseases Zura Bio develops biologics for serious autoimmune and inflammatory diseases, emphasizing combinations of validated immune pathways in single molecules. Tibulizumab Tibulizumab is a bispecific antibody designed to neutralize both IL-17 and BAFF. The dual mechanism targets inflammatory and B-cell...
Recent company news
ZURAZura Bio2026-08-31 20:30 EST
Zura Bio to Participate in the Cantor Global Healthcare Conference
ZURAZura Bio2026-08-21 23:57 EST
Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ZURAZura Bio2026-08-11 11:30 EST
Zura Bio Reports Second Quarter 2026 Financial Results and Recent Corporate Updates
ZURAZura Bio2026-06-29 11:30 EST
Zura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc) Phase 2 Studies and Expands Tibulizumab Program
ZURAZura Bio2026-05-14 11:30 EST
Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Stock data
- Close
- 4.57 USD
- Market cap
- 389.01M USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States